BioSpace News Archive

Hologic, Inc. announced the Company’s financial results for the fiscal third quarter ended June 26, 2021.

Inovalon, a leading provider of cloud-based platforms empowering data-driven healthcare, announced financial results for the second quarter of 2021, issued guidance for the third quarter of 2021, and raised guidance for revenue growth and reaffirmed profitability guidance for full-year 2021.

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2021.

CONMED Corporation announced financial results for the second quarter ended June 30, 2021.

Innoviva, Inc. reported financial results for the second quarter ended June 30, 2021.

M6P Therapeutics (“M6PT” or “the Company”), today announced pre-clinical proof-of-concept data on M041 in a poster presentation by Patricia Dickson, M.D., Centennial Professor of Pediatrics and Chief, Division of Genetics and Genomic Medicine, Washington University of St. Louis, titled “Recombinant human NAGLU with improved mannose 6-phosphorylation for Sanfilippo B syndrome” at the 16th Annual International Symposium of MPS and Related Diseases (“MPS 2021”).

Paragonix Technologies, Inc. announces that the University of Florida Health is the first to enroll a pediatric heart transplant recipient into the Company’s post-market registry, the Global Utilization And Registry Database for Improved preservAtion of donor HEARTs Pediatric Registry.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 4, 2021 to report its second quarter 2021 financial results and discuss recent business highlights.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), today announced that its President and CEO, Glenn Mattes, will be available for one-on-one meetings and will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:00pm EST.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced the initiation of patient dosing in UPGRADE, a Phase 1 combination dose escalation umbrella study to evaluate the safety and efficacy of upifitamab rilsodotin in combination with other ovarian cancer therapies.